Pfizer taps Dewpoint Therapeutics in $239M dystrophy drug deal

Dewpoint Therapeutics has added Pfizer to its growing list of pharma partners looking to tap the startup’s next-gen approach to a host of diseases.

The U.S.-German biotech is working on condensates, a new area of research that is helping explain aspects of cell biology that have been mysterious to researchers.

If you look back into your dog-eared biology textbooks, they'll almost certainly tell you the principle of the cell is the membrane.